Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Raw Materials (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Raw Materials data on record, last reported at $8.3 million in Q3 2025.

  • For Q3 2025, Raw Materials rose 98.31% year-over-year to $8.3 million; the TTM value through Sep 2025 reached $8.3 million, up 98.31%, while the annual FY2024 figure was $12.5 million, 20.68% up from the prior year.
  • Raw Materials reached $8.3 million in Q3 2025 per COLL's latest filing, down from $9.5 million in the prior quarter.
  • Across five years, Raw Materials topped out at $14.4 million in Q3 2023 and bottomed at $3.7 million in Q4 2021.
  • Average Raw Materials over 5 years is $7.7 million, with a median of $7.2 million recorded in 2024.
  • Peak YoY movement for Raw Materials: soared 149.84% in 2023, then crashed 70.8% in 2024.
  • A 5-year view of Raw Materials shows it stood at $3.7 million in 2021, then surged by 51.97% to $5.6 million in 2022, then skyrocketed by 85.43% to $10.4 million in 2023, then increased by 20.68% to $12.5 million in 2024, then tumbled by 33.48% to $8.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $8.3 million in Q3 2025, $9.5 million in Q2 2025, and $11.8 million in Q1 2025.